Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
Celgene Corporation
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT00633594
First received: March 4, 2008
Last updated: April 11, 2014
Last verified: April 2014

March 4, 2008
April 11, 2014
June 2008
November 2015   (final data collection date for primary outcome measure)
  • Determine Maximum Tolerated Dose (MTD) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    Determine the maximum tolerated dose (MTD) of the combination of lenalidomide, bortezomib, and rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL) who have received one prior therapy.
  • Assessment of safety and tolerability based on frequency of Adverse Events (AEs) [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
    Determine the safety and tolerability of the combination of lenalidomide, bortezomib, and rituximab in patients with previously untreated MCL and patients with relapsed or refractory MCL who have received one prior therapy
  • To determine the maximum tolerated dose (MTD) of the combination of lenalidomide, bortezomib, and rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL) who have received one prior therapy. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To determine the safety and tolerability of the combination of lenalidomide, bortezomib, and rituximab in patients with previously untreated MCL and patients with relapsed or refractory MCL who have received one prior therapy [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00633594 on ClinicalTrials.gov Archive Site
  • To make preliminary estimates of the efficacy of the combination of lenalidomide, bortezomib, and rituximab in patients with previously untreated MCL and patients with relapsed or refractory MCL who have received one prior therapy. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Determine time to best response, duration of response, progression-free survival (PFS), and overall survival. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To make preliminary estimates of the efficacy of the combination of lenalidomide, bortezomib, and rituximab in patients with previously untreated MCL and patients with relapsed or refractory MCL who have received one prior therapy. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To determine time to best response, duration of response, progression-free survival (PFS), and overall survival. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Phase I/II Study Evaluating Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients With Mantle Cell Lymphoma

This is a Phase I/II multicenter, open-label, dose-escalation study of rituximab, bortezomib, and lenalidomide in the first-line or second-line treatment of patients with Mantle Cell Lymphoma (MCL).

The combination of lenalidomide with bortezomib has not been studied in patients with MCL, but feasibility and tolerability has been demonstrated in patients with multiple myeloma. Thus, almost every 2-drug combination of rituximab, lenalidomide, and bortezomib has been tested, or is being tested. We hypothesize that all three drugs are important in MCL, and therefore propose to combine all 3 agents (rituximab, bortezomib, and lenalidomide) in a schedule that is convenient to lymphoma patients.

Approximately 18 patients may be enrolled in the Phase I portion of the study. Approximately 45 patients are planned for enrollment in Phase II.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Mantle Cell Lymphoma
  • Drug: Rituximab
    Other Names:
    • Rituxan
    • MabThera
  • Drug: Bortezomib
    Other Name: Velcade
  • Drug: Lenalidomide
    Other Name: Revlimid
Experimental: rituximab/bortezomib/lenalidomide

Patients in Phase I & II will receive treatment with rituximab, bortezomib and lenalidomide in 21-day cycles.

Phase I: patients in Cohort 1 will receive Dose Level 1:

  • Cycle 1: rituximab 375 mg/m2 intravenously (IV) on Days 1, 8, 15; bortezomib 1.3 mg/ m2 SC on Days 1, 4, 8, 11; lenalidomide 15 mg by mouth (PO) daily on Days 1-14.
  • Cycles 2-6: rituximab 375 mg/m2 IV on Day 1; bortezomib 1.3 mg/ m2 SC on Days 1, 4, 8, 11; lenalidomide 15 mg PO daily on Days 1-14.

Doses will be escalated in subsequent cohorts as per protocol; doses may be de-escalated if necessary. Patients in Phase II will be treated with the DL-1 dose determined in Phase I. If patients experience no treatment-related AEs after 2 cycles, the treating physician has the option of escalating to DL1 for subsequent cycles.

Interventions:
  • Drug: Rituximab
  • Drug: Bortezomib
  • Drug: Lenalidomide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
58
December 2015
November 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histology: biopsy-proven mantle cell lymphoma (MCL).
  2. Prior therapy: both newly diagnosed patients and relapsed or refractory patients who have received one prior therapy are eligible. Patients who have previously received high-dose chemotherapy with peripheral stem cell support are eligible. Newly diagnosed patients are eligible for the Phase II portion of the study only.
  3. Presence of at least one lymph node evaluable or mass measurable for response.
  4. Platelets > 75,000/µL and absolute neutrophil count (ANC) > 1,000/µL within 14 days of study registration (unless the treating physician deems the neutropenia is related to bone marrow involvement, then an ANC of > 750/mm3 is allowed).
  5. Calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault method within 14 days of study registration.
  6. ECOG performance of 0, 1, or 2.
  7. Age greater than or equal to 18 years.
  8. Recovery from any previous treatment therapy.
  9. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 14 days prior and again within 24 hours of starting lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by RevAssist) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
  10. All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
  11. Ability to understand and willingness to voluntarily sign a written informed consent document before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Exclusion Criteria:

  1. Patient has 1.5 x ULN total bilirubin.
  2. Peripheral neuropathy ≥ CTCAE grade 2.
  3. Pregnant or breastfeeding females. (Lactating females must agree not to breastfeed while taking lenalidomide.)
  4. Thrombolic or embolic events (such as a cerebrovascular accident, including transient ischemic attacks) within the past 6 months.
  5. Pulmonary hemorrhage/bleeding event less than or equal to CTCAE grade 2 within 28 days of the first dose of study drug.
  6. Female patients who have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on DAY 1 before first dose of study drug, if applicable.
  7. Thrombolic or embolic events (such as a cerebrovascular accident, including transient ischemic attacks) within the past 6 months.
  8. Pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within 28 days of the first dose of study drug.
  9. Any other hemorrhage/bleeding event ≥ CTCAE grade 3 ≤ 28 days of the first dose of study drug
  10. Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis.
  11. Central nervous system (CNS) involvement by lymphoma at time of enrollment.
  12. Other medical conditions or psychiatric illness that would potentially interfere with patient participation in this trial.
  13. A second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least 2 years previously.
  14. Previous evidence of hypersensitivity to bortezomib, boron, mannitol, thalidomide, or rituximab (true anaphylaxis, not a rituximab-infusion reaction).
  15. Known human immunodeficiency virus (HIV) infection or chronic hepatitis A, B, or C. Patients who are HIV positive or who are positive for chronic hepatitis A, B, or C will be excluded due to increased risk for bone marrow suppression and other toxicities.
  16. Active, clinically serious infection > CTCAE grade 2. Patients may be eligible upon resolution of the infection.
  17. Evidence or history of bleeding diathesis or coagulopathy.
  18. Major surgery, open biopsy, or significant traumatic injury within 28 days of the first dose of study drug.
  19. Use of any other standard chemotherapy, radiation therapy, or experimental drug for the treatment of MCL within 28 days of starting treatment.
  20. Any condition that impairs a patient's ability to swallow whole pills. Impairment of gastrointestinal function (GI) or GI disease that may significantly alter the absorption of lenalidomide (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  21. Patients with grade 3/4 cardiac problems, as defined by the New York Heart Association (NYHA) criteria or any of the following:

    • History of uncontrolled or symptomatic angina
    • History of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation
    • Myocardial infarction < 6 months from study entry
    • Uncontrolled or symptomatic congestive heart failure
    • Ejection fraction below the institutional normal limit
    • Electrocardiographic evidence of acute ischemia or active conduction system abnormalities
    • Any other cardiac condition that, in the opinion of the treatment physician, would make this protocol unreasonably hazardous for the patient

21. Uncontrolled hypertension (systolic blood pressure [BP] > 180 or diastolic BP > 100mm Hg) or uncontrolled cardiac arrhythmias.

22. Any prior use of lenalidomide.

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00633594
SCRI LYM 58
No
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
  • Millennium Pharmaceuticals, Inc.
  • Celgene Corporation
Study Chair: Ian W Flinn, M.D. SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP